Exidavnemab is a monoclonal antibody designed to eliminate aggregated clumps of the protein biomarker and slow progression of Parkinson's disease.
Monday said Phase 3 TEMPO-2 study evaluating tavapadon in early Parkinson's disease met its primary goal. In the ...
We here at EdExec pride ourselves in creating solutions for suppliers to deliver their message in the most effective and ...
A study from the University of Arizona shows that the protein PNA5 helps protect brain cells, offering a promising avenue for treating cognitive symptoms in Parkinson’s disease, a condition currently ...